<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033119</url>
  </required_header>
  <id_info>
    <org_study_id>N-20210029</org_study_id>
    <nct_id>NCT05033119</nct_id>
  </id_info>
  <brief_title>PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics</brief_title>
  <acronym>PROSA</acronym>
  <official_title>PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulla Schierup Nielsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Denmark Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Denmark Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mental Health Services in the Capital Region, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        1. To determine the prevalence and degree of hyperprolactinemia in children and adolescents&#xD;
           aged 7-18 years receiving antipsychotic medications&#xD;
&#xD;
        2. To determine the associations between serum-prolactin and sex hormones / metabolic&#xD;
           biomarkers/ clinical symptoms in this population. If clinically relevant associations&#xD;
           are found: To determine a potentially existing &quot;no harm&quot; serum-prolactin threshold&#xD;
&#xD;
        3. To determine associations between previous cumulative prolactin-exposure and current&#xD;
           pubertal development / growth&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of hyperprolactinemia</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>associations between serum-prolactin and sex hormones / metabolic biomarkers / clinical symptoms</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>associations between previous prolactin-exposure and current pubertal development / growth</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Hyperprolactinemia</condition>
  <condition>Puberty Disorders</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Growth Disorders</condition>
  <condition>Antipsychotics and Neuroleptics Toxicity</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All outpatients aged 7-18 years receiving treatment with antipsychotics at the Department&#xD;
        of Child and Adolescent Psychiatry, Aalborg University Hospital, the Department of Child&#xD;
        and Adolescent Psychiatry, Aarhus University Hospital and at the Child and Adolescent&#xD;
        Mental Health Center, Copenhagen University Hospital, Capital Region will be invited to&#xD;
        participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â€¢ In daily treatment with antipsychotic medication belonging to Anatomical Therapeutic&#xD;
             Chemical (ATC) group N05A (except N05AN lithium) for a minimum duration of 3 months&#xD;
             prior to inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eating Disorder&#xD;
&#xD;
          -  Medical treatment to change sex&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla S Nielsen</last_name>
    <role>Study Director</role>
    <affiliation>Research Unit for Child and Adolescent Psychiatry, Aalborg,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulla S Nielsen</last_name>
    <phone>+4530289283</phone>
    <email>uni@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morten B Thorsen</last_name>
    <phone>+4524 22 82 56</phone>
    <email>morten.thorsen@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Unit for Child and Adolescent Psychiatry, Aalborg University Hospital, Denmark</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child and Adolescent Mental Health Center Capital Region, Denmark</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Psychiatric Hospital</investigator_affiliation>
    <investigator_full_name>Ulla Schierup Nielsen</investigator_full_name>
    <investigator_title>National Coordinating Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

